Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® (vigabatrin) Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA).
The Sabril® brand and generic had U.S. sales of approximately $274 million MAT for the most recent twelve months ending in June 2019 according to IMS Health*.
Dr. Reddy's Vigabatrin Powder for Oral Solution, USP is available in 500 mg per packet in count size of 50 per carton.
Sabril® is a trademark of Lundbeck.
Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.2509.6 as compared to the previous close of Rs. 2492.8. The total number of shares traded during the day was 20292 in over 1607 trades.
The stock hit an intraday high of Rs. 2567.5 and intraday low of 2503. The net turnover during the day was Rs. 51499499.